Question
A 62-year-old woman comes to the emergency unit with marked nausea, upper abdominal discomfort, and occasional loose stools after recently starting a new antidiabetic drug.
She was initiated on immediate-release metformin 500 mg three times daily by her doctor.
She has a background of newly diagnosed type 2 diabetes and a past history of bladder malignancy. No drug allergies are reported.
Recent labs (3 weeks ago):
HbA1c: 57 mmol/mol
What is the most appropriate next step in management?
a) Change to a DPP-4 inhibitor
b) Initiate insulin therapy
c) Switch to extended-release metformin
d) Start a sulfonylurea
e) Begin thiazolidinedione
Answer
Switch to extended-release metformin
Detailed Explanation
This patient is experiencing classic gastrointestinal intolerance (nausea, epigastric pain, diarrhoea) due to metformin, which is extremely common, especially with immediate-release formulations and higher doses.
Key clinical reasoning:
- Metformin is first-line therapy in type 2 diabetes → should not be abandoned prematurely.
- GI side effects occur in up to 20% of patients.
- The first step is NOT to switch drug class, but to improve tolerability.
Why modified-release metformin?
- Slower absorption → less GI irritation
- Maintains efficacy while improving compliance
- Recommended by guidelines before moving to second-line therapy
Why not other options?
- Sulfonylureas → risk of hypoglycaemia
- Insulin → too early, HbA1c not severely uncontrolled
- Pioglitazone → contraindicated in bladder cancer history
- DPP-4 inhibitors → only after metformin intolerance confirmed
Cheat Sheet for Exam
Metformin intolerance approach:
- Start low, go slow (dose titration)
- If GI symptoms → switch to modified-release
- If still intolerant → switch to second-line drug
Important contraindications:
- eGFR <30 → stop
- Bladder cancer → avoid pioglitazone
- Acute illness (sepsis, MI) → risk of lactic acidosis
Exam pearls:
- Metformin = first-line unless contraindicated
- GI side effects ≠indication to stop immediately
- Always try modified-release first
Flash Cards
Q1: What is the most common side effect of metformin?
A: Gastrointestinal upset (nausea, diarrhoea)
Explanation: Due to local gut effects and dose-related intolerance
Q2: What is the first step if metformin causes GI intolerance?
A: Switch to modified-release metformin
Explanation: Improves tolerability without losing efficacy
Q3: Which antidiabetic drug is contraindicated in bladder cancer?
A: Pioglitazone
Explanation: Associated with increased bladder cancer risk
Q4: Does metformin cause hypoglycaemia?
A: No
Explanation: It improves insulin sensitivity without increasing insulin secretion
MCQs
1. A patient develops diarrhoea after starting metformin. What is the best next step?
a) Stop metformin immediately
b) Add insulin
c) Switch to modified-release metformin
d) Add sulfonylurea
Answer: c
Explanation: First step is to improve tolerability using modified-release formulation before abandoning metformin.
2. Which of the following is FALSE regarding metformin?
a) It reduces hepatic gluconeogenesis
b) It causes frequent hypoglycaemia
c) It improves insulin sensitivity
d) It may reduce carbohydrate absorption
Answer: b
Explanation: Metformin does NOT cause hypoglycaemia.
3. Which drug should be avoided in a patient with previous bladder cancer?
a) Metformin
b) Sitagliptin
c) Pioglitazone
d) Insulin
Answer: c
Explanation: Pioglitazone is associated with bladder cancer risk.
4. A patient cannot tolerate modified-release metformin. What is next step?
a) Continue same drug
b) Switch to second-line oral agent
c) Add aspirin
d) Stop all therapy
Answer: b
Explanation: After failure of modified-release, move to second-line drugs like sulfonylureas or DPP-4 inhibitors.
5. Which of the following situations requires stopping metformin?
a) Mild diarrhoea
b) eGFR <30 ml/min
c) HbA1c >50 mmol/mol
d) Age >60
Answer: b
Explanation: Severe renal impairment increases risk of lactic acidosis.
Summary for Quick Exam Revision
Metformin is the first-line drug for type 2 diabetes due to its efficacy, weight neutrality, and low hypoglycaemia risk. However, gastrointestinal side effects such as nausea and diarrhoea are common, especially with immediate-release formulations and higher doses. The correct approach is not to discontinue metformin immediately but to improve tolerability by switching to a modified-release preparation. This maintains glycaemic control while reducing adverse effects. Only if modified-release metformin is not tolerated should second-line agents such as sulfonylureas or DPP-4 inhibitors be considered. Pioglitazone must be avoided in patients with a history of bladder cancer. Insulin is reserved for cases with poor glycaemic control despite oral therapy. Renal function must always be assessed, as metformin is contraindicated in severe renal impairment due to risk of lactic acidosis. Overall, exam questions frequently test the principle: always try modified-release metformin before switching therapy.